IHC ER PR HER2 Neu Test: Comprehensive Breast Cancer Biomarker Analysis
Understanding the IHC ER PR HER2 Neu Test
The IHC ER PR HER2 Neu test represents a cornerstone in modern breast cancer diagnostics, providing essential information that directly influences treatment decisions and patient outcomes. This sophisticated immunohistochemistry analysis evaluates three critical biomarkers that determine the molecular characteristics of breast cancer cells, enabling personalized medicine approaches that target the specific biological drivers of each patient’s cancer.
What Does the IHC ER PR HER2 Neu Test Measure?
This comprehensive test analyzes three key protein receptors in breast cancer tissue:
- Estrogen Receptors (ER): Proteins that bind estrogen and promote cancer cell growth
- Progesterone Receptors (PR): Proteins that respond to progesterone and influence tumor behavior
- HER2/neu Protein: A growth-promoting receptor that can drive aggressive cancer growth when overexpressed
Who Should Consider This Test?
The IHC ER PR HER2 Neu test is essential for individuals with:
- Newly diagnosed breast cancer
- Suspicious breast lumps or abnormal mammogram findings
- Recurrent breast cancer requiring updated biomarker analysis
- Metastatic breast cancer to determine treatment options
- Family history of breast cancer with current diagnostic concerns
Clinical Benefits of IHC ER PR HER2 Neu Testing
This advanced biomarker analysis provides numerous clinical advantages:
- Personalized Treatment Planning: Identifies which targeted therapies will be most effective
- Hormone Therapy Guidance: Determines eligibility for endocrine treatments like tamoxifen or aromatase inhibitors
- HER2-Targeted Therapy Selection: Identifies candidates for drugs like Herceptin or Perjeta
- Prognostic Information: Helps predict disease course and recurrence risk
- Clinical Trial Eligibility: Determines qualification for specific research studies
Understanding Your Test Results
Your IHC ER PR HER2 Neu results will provide detailed information about biomarker expression:
Estrogen Receptor (ER) Results
- Positive: Cancer cells have estrogen receptors, indicating potential response to hormone therapy
- Negative: No estrogen receptors present, suggesting alternative treatment approaches
Progesterone Receptor (PR) Results
- Positive: Presence of progesterone receptors supports hormone-sensitive cancer classification
- Negative: Absence of progesterone receptors may indicate different cancer subtype
HER2/neu Results
- Positive (3+): Strong HER2 protein overexpression, indicating eligibility for HER2-targeted therapies
- Equivocal (2+): Moderate HER2 expression requiring additional FISH testing for confirmation
- Negative (0 or 1+): No significant HER2 overexpression
Test Pricing and Details
| Test Component | Details |
|---|---|
| Test Name | IHC ER PR HER2 Neu |
| Regular Price | $150 USD |
| Discount Price | $112 USD |
| Turnaround Time | 3 Days |
| Sample Type | Tissue/Paraffin Block |
| Test Components | Tissue in 10% Neutral Buffered Formalin or Block |
Convenient Testing Locations Across the USA
GGC DNA maintains comprehensive testing facilities throughout major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our nationwide network ensures accessible, reliable testing services with consistent quality standards and rapid result delivery.
Take Control of Your Breast Cancer Journey
Don’t leave your treatment decisions to chance. The IHC ER PR HER2 Neu test provides the critical biomarker information needed to develop the most effective, personalized cancer treatment strategy. With results available in just 3 days and our special discounted price of $112 USD, there’s no reason to delay this essential diagnostic step.
Ready to schedule your test? Call or WhatsApp us today at +1(267) 388-9828 to book your appointment or speak with our oncology testing specialists.
Note: IHC ER PR HER2 Neu testing requires a doctor’s prescription. Prescription requirements do not apply to surgery and pregnancy cases or individuals planning international travel.
